Background {#Sec1}
==========

Among retinal vascular pathologies branch retinal vein occlusion (BRVO) was reported to be the second most common entity after diabetic retinopathy, with a cumulative 15-year incidence of 1.8 % \[[@CR1]\]. BRVO mostly occurs at arterio-venous crossing sites, explaining the contribution of arteriosclerosis in adjacent arteries \[[@CR2]\]. It is associated with cardiovascular risk factors and pathogenically follows the principle of Virchow's triad (stasis, hypercoagulability and endothelial damage) \[[@CR3]\]. BRVO is frequently associated with macular edema (ME) as the endothelial damage results in an inflammatory response of affected vessels with subsequent up-regulation of inflammatory mediators such as TNF-alpha, prostaglandins, leukotriens, integrins and vascular endothelial growth factor (VEGF) \[[@CR4], [@CR5]\]. Studies showed that VEGF plays a major role in the evolution and persistence of secondary ME \[[@CR6]\]. Earlier treatment of ME was reported to be associated with better results in terms of long-term visual acuity \[[@CR7]\].

For many years, the gold standard treatment for macular edema in BRVO was grid laser photocoagulation \[[@CR8]\]. With the advent of anti-VEGF compounds first-line treatment strategies of ME in BRVO are intravitreal anti-VEGF agents \[ranibizumab (Lucentis ©, Novartis), bevacizumab (Avastin ©, Genentech) and aflibercept (Eylea ©, Regeneron Pharmaceuticals Inc.)\]. In comparison to grid laser photocoagulation, the use of aflibercept led to a significant visual benefit and reduction in central retinal thickness (CRT) in eyes with macular edema secondary to BRVO as reported in the VIBRANT study \[[@CR9]\].

Aflibercept, the most recently developed anti-VEGF agent, is a 115-kDa soluble receptor fusion protein consisting of the second domain of VEGF receptor 1 and the third domain of VEGF receptor 2 fused to the Fc domain of immunoglobulin G1. In contrast to other anti-VEGF agents, aflibercept additionally binds PGF (placental derived growth factor) and has a considerably higher binding affinity for VEGF \[[@CR10], [@CR11]\]. Furthermore a longer duration of action was reported, which contributed to the recent approval for macular edema in CRVO \[[@CR12]\]. Experience with aflibercept in patients with CRVO and ME insufficiently responding to prior anti-VEGF showed favorable outcomes \[[@CR13], [@CR14]\].

The current study was designed to evaluate the change of injection interval and clinical outcomes in patients who have been treated with aflibercept for at least 12 months as a consequence of an insufficient response to ranibizumab and/or bevacizumab.

Methods {#Sec2}
=======

This retrospective clinical study was conducted at the department of ophthalmology, City hospital Triemli Zurich and was approved by the local ethics committee (Ethics Commission of the Canton Zurich, KEK-ZH-Nr. 2014-0601). Its conduction adhered to the tenets of the declaration of Helsinki. Included patients (n = 10) gave their written informed consent on retrospective data evaluation and its publication. Data were retrieved from an internal database, containing clinical information of all patients treated with anti-VEGF agents during the past 3 years (2012--2015). In addition medical charts and optical coherence tomography scans (OCT) of included patients were reviewed.

Patients of Caucasian descent in whom therapy was changed to off-label aflibercept as an individual case decision, after an insufficient response to treatment with bevacizumab or ranibizumab, were included in this case series. Insufficient response was defined as the necessity of injection intervals of 6 weeks or less, elicited by the persistence or any increase of intraretinal fluid as imaged by spectral-domain optical coherence tomography (Heidelberg Spectralis **©** System). Evidence of increasing or persistent fluid in any of the 19 standard scans (512 A---scans, 20° × 15°) was considered as disease-related activity.

All intravitreal injections were administered according to a "treat and extend" regimen \[[@CR15]\]. This protocol is characterized by the adjustment of individual injection intervals according to therapeutic response. The main objective of this protocol is to reduce the treatment burden for the patient, considering risks and inconveniences each injection carries, as well as economic aspects. At each visit OCT scans were evaluated for alterations of intraretinal and subretinal fluid. The absence of any activity sign (increasing and/or persistent fluid) resulted in a prolongation of the current injection interval by 2 weeks and vice versa.

The primary outcome was the change in the mean injection interval comparing baseline (prior to treatment with aflibercept) to month 12 after switching to aflibercept. Secondary outcomes included: best-corrected visual acuity (BCVA), central retinal thickness (CRT), central retinal volume (CRV) (6 mm diameter, 512 A---scans, 20° × 15°) and intraocular pressure (IOP, as measured by air-puff tonometry). For statistical purposes, visual acuity measures (registered as Snellen acuity fractions) were converted into ETDRS scores (Early Treatment Diabetic Retinopathy Study) as described by Gregori et al. \[[@CR16]\]. Information on CRT and CRV was retrieved from spectral- domain optical coherence tomography (SD-OCT) scans (Heidelberg Spectralis © System, Heidelberg Engineering). OCT images at month 6 and 12 were taken using the SLO-based (scanning laser ophthalmoscope) eye tracking system (AutoRescan), ensuring the correct location for follow-up.

Statistical analyses were performed using SPSS^**®**^ Version 20 and Microsoft Office Excel for Windows, Version 2007. Binomial and exact Wilcoxon signed rank tests were employed for asymmetrical (visual acuity, central retinal thickness and volume, injection interval) and symmetrical (IOP) distributions of differences, respectively.

Results {#Sec3}
=======

Ten eyes (n = 10) of ten patients with macular edema secondary to BRVO were included in the current retrospective analysis. These patients received aflibercept after an initial insufficient response (criteria see above) to treatment with ranibizumab and/or bevacizumab.

The study group consisted of 8 male and 2 female patients. Mean age at baseline amounted to 73.9 ± 5.2 years.

Eight patients were pretreated with ranibizumab, 1 patient was pretreated with bevacizumab intravitreal injections and 1 patient was pretreated with both anti-VEGF agents. At baseline (pre-aflibercept), patients had received a mean of 15.5 (SD ± 5.02) injections during a mean period of 23.1 (SD ± 13.8) months (range 10--53 months). During the 10--12 months prior switching treatment to aflibercept, included patients received a mean of 10.0 injections.

The mean injection interval---as primary outcome---increased from 5.0 ± 1.6 weeks at baseline (prior therapy change) to 8.5 ± 3.3 weeks at month 6 and 8.3 ± 2.1 weeks at month 12 (p = 0.002) (Fig. [1](#Fig1){ref-type="fig"}). This resulted in a mean prolongation of 3.3 ± 1.8 weeks throughout the observation period.Fig. 1Injection interval (median, SD): change from baseline to month 12 (p = 0.002)

As functional and secondary outcome, BCVA fluctuated from 72.7 ± 15.2 letters at baseline to 72.2 ± 15.2 letters at month 6 and 77.9 ± 6.8 letters at month 12 (Fig. [2](#Fig2){ref-type="fig"}). The gain of 5.2 (SD ± 11.0) letters after 12 months did not reach the level of statistical significance (p = 0.375). From initial diagnosis to baseline (therapy switch to aflibercept) a mean gain of 10.3 ± 11.0 letters was measured.Fig. 2Visual acuity (median, SD): change from baseline to month 12 (p = 0.375)

Secondary anatomical outcomes, such as the mean CRT and mean CRV likewise indicated an improvement. Pretreatment CRT amounted to 453.8 ± 122.2 µm. CRT decreased from 373.2 ± 195.1 µm at baseline to 351.0 ± 226.9 µm at month 6 and 311.5 ± 95.1 µm at month 12. The mean reduction of 61.7 µm ± 192.1 did not reach the level of statistical significance (p = 0.344) (Fig. [3](#Fig3){ref-type="fig"}). Analogously, CRV was reduced from 9.5 ± 1.9 mm^3^ at baseline to 9.4 ± 2.7 mm^3^ at month 6 and 8.6 ± 1.1 mm^3^ at month 12. This resulted in a mean reduction of 0.9 ± 2.4 mm^3^ within the treatment period of 12 months (p = 0.021). Pretreatment values amounted to 11.2 ± 3.1 mm^3^ (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Central retinal thickness (mean, SD): change from baseline to month 12 (p = 0.344) Fig. 4Central retinal volume (mean, SD): change from baseline to month 12 (p = 0.021)

Intraocular pressure values were not significantly affected by aflibercept intravitreal injections during the study period (p = 0.238).

Discussion {#Sec4}
==========

Our data indicate that by switching anti-VEGF therapy to aflibercept in eyes with chronic, recurrent ME due to BRVO a significant extension of the injection interval can be obtained. Our data do not allow a definite conclusion since the study was not controlled and included only a small number of patients. However, it appears rather unlikely that a chronic recurrent ME in BRVO shows on average almost half the need for treatment within 6 months (extension of treatment intervals by a mean of 3.5 weeks). Nevertheless, the substantive range of injection intervals (±3.3 weeks) at month 12 must be considered concerning this matter. The further follow-up (month 6--12) showed no further relevant change in the treatment interval, indicating that rather the change in therapy than a continuous regression of disease activity is the origin of extended treatment intervals. A spontaneous regression in the natural course of macular edema secondary to BRVO as described by Rogers et al. \[[@CR17]\] appears rather unlikely since patients with recurrent chronic ME were selected.

The rationale for this finding is likely related to different properties of aflibercept (higher VEGF binding affinity, additional PGF binding) compared to ranibizumab and bevacizumab \[[@CR10], [@CR11]\]. Recently presented data demonstrated the longest intravitreal retention time for aflibercept in comparison to bevacizumab and ranibizumab \[[@CR18]\]. Analysis of intraocular VEGF levels in humans following intravitreal aflibercept administration indicated that VEGF was suppressed below the lower limit of quantification for 10 weeks on average \[[@CR19]\].

Functional and anatomic outcomes (CRT, CRV, BCVA) showed some improvement during the whole study period after therapy change to aflibercept (baseline to month 12). However, only a minority of parameters showed statistically significant changes. This has to be seen in the context that all eyes had been extensively treated prior to change of therapy and that they had a significant increase in their visual acuity (+10.3 letters) from prior to any therapy to baseline. Therefore, the additional potential functional and anatomic gain already was limited.

Since only two patients were pretreated with bevacizumab, comparison of outcomes between the two types of anti-VEGF pretreatments (ranibizumab/bevacizumab) was not judged as expedient in our analysis.

Due to lack of data for aflibercept in BRVO, no comparison with existing studies can be made. Pfau et al. indicate superior results of aflibercept in CRVO as compared to prior ranibizumab/bevacizumab treatment \[[@CR13]\]. Since edema secondary to BRVO in the majority of cases is less pronounced than in CRVO, a less measurable improvement following treatment may be a consequence.

Conclusions {#Sec5}
===========

In conclusion, our retrospective analysis showed a statistically significant and clinically relevant prolongation of injection intervals within 12 months following a change of anti-VEGF therapy in patients with chronic recurrent ME secondary to BRVO. However, improvements regarding BCVA and CRT were limited. Larger prospective, clinical trials are required not only to confirm less need for treatment with aflibercept, but also to clearly demonstrate a functional and anatomic benefit by changing anti-VEGF agents.

Limitations {#Sec6}
-----------

The small number of patients, the lack of a control group and the retrospective study design not only inhere the risk of type 1 and type 2 errors, but also of selection and performance bias. Moreover, interobserver variability must be mentioned as a potential source of bias.
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